Kidney Fibrosis: Lock out SIRT4
Chronic kidney disease is estimated to affect over 10% of the global population (Kovesdy, 2022). Its most common feature is kidney fibrosis, which is characterized by the accumulation of extracellular matrix proteins in tissues, causing structural damage that can impair the function of the kidneys (Huang et al., 2023).
Previous work revealed that complex mechanisms and protein mediators drive kidney fibrosis, including the protein TGF-β1, which plays a vital role in promoting the expression of pro-fibrotic genes. TGF-β1 acts through a well-established signaling pathway that eventually activates a set of three transcription factors – Smad2, Smad3 and Smad4 – which collectively move from the cytoplasm to the nucleus where they promote the transcription of pro-fibrotic genes (Meng et al., 2016). The transport of molecules from the cytoplasm to the nucleus occurs continuously in cells throughout the body and must be tightly controlled to prevent aberrant traffic that can drive disease.
However, directly inhibiting TGF-β1 signaling to prevent kidney fibrosis is not an ideal therapeutic strategy due to the potential adverse effects of disrupting other biological processes involving TGF-β1. Therefore, a greater understanding of the mechanisms underlying TGF-β1-induced fibrosis is required to identify alternative approaches. Now, in eLife, Lin Kang, Zhen Liang, Shu Yang and colleagues – including Guangyan Yang, Jiaqing Xiang and Xiaoxiao Yang as joint first authors – report how unusual TGF-β1-driven translocation of the protein Sirtuin 4 into the nucleus contributes to the progression of kidney fibrosis (Yang et al., 2024).
Sirtuin 4 (also known as SIRT4 for short) is normally located in the mitochondria. However, Yang et al. (who are based at the First Affiliated Hospital of Southern University of Science and Technology and Hefei University of Technology) found increased amounts of SIRT4 in the nuclei of kidney cells from patients with chronic kidney disease. Similarly, they also discovered elevated levels of nuclear SIRT4 in the kidneys of mice that had been injured during surgery to induce kidney fibrosis experimentally.
Intriguingly, Yang et al. found that deleting the gene for SIRT4 significantly reduced the extent of kidney fibrosis in mice following an injury; this occurred either globally throughout the body or specifically in the epithelial cells lining tubules in the kidney. Consistent with this finding, overexpressing the gene in the same cells markedly enhanced the extent of kidney fibrosis. Taken together, these results suggest that abnormal nuclear accumulation of SIRT4 contributes to kidney fibrosis.
To investigate the mechanism underlying SIRT4-mediated fibrosis, Yang et al. carried out experiments in human kidney tubule epithelial cells to identify which proteins interact with SIRT4 upon TGF-β1 treatment. Interestingly, SIRT4 interacted with several proteins that localized in the nucleus, including U2AF2 (short for U2 small nuclear RNA auxiliary factor 2). This protein plays an important role in assembling the molecular machinery known as a spliceosome, which removes unnecessary parts of pre-mRNA to form the mature mRNA that is translated into a protein (Zorio and Blumenthal, 1999; Agrawal et al., 2016).
Yang et al. found that TGF-β1 treatment induced SIRT4 to remove acetyl groups from U2AF2. This allowed U2AF2 to splice the pre-mRNA of a pro-fibrotic protein called CCN2 (short for cell communication network 2), causing expression of this protein to increase. Together, these findings identify the SIRT4-U2AF2-CCN2 axis as a novel mechanism of TGF-β1-induced kidney fibrosis (Figure 1).
Yang et al. next set out to explore how SIRT4 translocates from the mitochondria to the nucleus upon TGF-β1 treatment. The experiments showed that TGF-β1-induced release of SIRT4 from mitochondria occurs through pores formed by protein polymers known as BAX and BAK, which are located in the outer membrane of mitochondria (Cosentino and García-Sáez, 2017). Screening using a variety of protein inhibitors demonstrated that in order to translocate, SIRT4 must be phosphorylated by enzymes known as ERK1 and ERK2. This modification allows SIRT4 to bind to a nuclear-transport receptor called importin α1, which moves the protein into the nucleus. Finally, Yang et al. treated mice with anti-SIRT4 antibodies that only inhibit expression of SIRT4 in the nucleus, and found this targeted disruption could sufficiently alleviate surgery-induced kidney fibrosis.
These findings open an exciting avenue for the development of a novel therapeutic strategy against kidney fibrosis: to lock the ‘bad guy’ – SIRT4 – out of the nuclei of kidney cells. It is conceivable that in the future, small molecules that hinder SIRT4 from interacting with ERK1/2 or importin α1 could be screened or synthesized to treat kidney fibrosis. However, nuclear SIRT4 may play beneficial roles in other cells and tissues (Zeng et al., 2018), thus further clinical studies are needed to evaluate the safety of such a strategy.
References
-
An extended U2AF(65)-RNA-binding domain recognizes the 3’ splice site signalNature Communications 7:10950.https://doi.org/10.1038/ncomms10950
-
Bax and Bak pores: Are we closing the circle?Trends in Cell Biology 27:266–275.https://doi.org/10.1016/j.tcb.2016.11.004
-
Kidney fibrosis: from mechanisms to therapeutic medicinesSignal Transduction and Targeted Therapy 8:129.https://doi.org/10.1038/s41392-023-01379-7
-
Epidemiology of chronic kidney disease: an update 2022Kidney International Supplements 12:7–11.https://doi.org/10.1016/j.kisu.2021.11.003
-
TGF-β: the master regulator of fibrosisNature Reviews Nephrology 12:325–338.https://doi.org/10.1038/nrneph.2016.48
Article and author information
Author details
Publication history
Copyright
© 2024, Zhao and Zhou
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 168
- views
-
- 21
- downloads
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Cell Biology
- Developmental Biology
The bone-resorbing activity of osteoclasts plays a critical role in the life-long remodeling of our bones that is perturbed in many bone loss diseases. Multinucleated osteoclasts are formed by the fusion of precursor cells, and larger cells – generated by an increased number of cell fusion events – have higher resorptive activity. We find that osteoclast fusion and bone resorption are promoted by reactive oxygen species (ROS) signaling and by an unconventional low molecular weight species of La protein, located at the osteoclast surface. Here, we develop the hypothesis that La’s unique regulatory role in osteoclast multinucleation and function is controlled by an ROS switch in La trafficking. Using antibodies that recognize reduced or oxidized species of La, we find that differentiating osteoclasts enrich an oxidized species of La at the cell surface, which is distinct from the reduced La species conventionally localized within cell nuclei. ROS signaling triggers the shift from reduced to oxidized La species, its dephosphorylation and delivery to the surface of osteoclasts, where La promotes multinucleation and resorptive activity. Moreover, intracellular ROS signaling in differentiating osteoclasts oxidizes critical cysteine residues in the C-terminal half of La, producing this unconventional La species that promotes osteoclast fusion. Our findings suggest that redox signaling induces changes in the location and function of La and may represent a promising target for novel skeletal therapies.
-
- Cell Biology
The β-catenin-dependent canonical Wnt signaling is pivotal in organ development, tissue homeostasis, and cancer. Here, we identified an upstream enhancer of Ctnnb1 – the coding gene for β-catenin, named ieCtnnb1 (intestinal enhancer of Ctnnb1), which is crucial for intestinal homeostasis. ieCtnnb1 is predominantly active in the base of small intestinal crypts and throughout the epithelia of large intestine. Knockout of ieCtnnb1 led to a reduction in Ctnnb1 transcription, compromising the canonical Wnt signaling in intestinal crypts. Single-cell sequencing revealed that ieCtnnb1 knockout altered epithelial compositions and potentially compromised functions of small intestinal crypts. While deletion of ieCtnnb1 hampered epithelial turnovers in physiologic conditions, it prevented occurrence and progression of Wnt/β-catenin-driven colorectal cancers. Human ieCTNNB1 drove reporter gene expression in a pattern highly similar to mouse ieCtnnb1. ieCTNNB1 contains a single-nucleotide polymorphism associated with CTNNB1 expression levels in human gastrointestinal epithelia. The enhancer activity of ieCTNNB1 in colorectal cancer tissues was stronger than that in adjacent normal tissues. HNF4α and phosphorylated CREB1 were identified as key trans-factors binding to ieCTNNB1 and regulating CTNNB1 transcription. Together, these findings unveil an enhancer-dependent mechanism controlling the dosage of Wnt signaling and homeostasis in intestinal epithelia.